Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
Summary · Treatments & Research

Recent developments regarding the treatment and research of multiple myeloma indicate promising advances. [USA] A new bispecific antibody targeting BCMA is being tested in patients with relapsed multiple myeloma, while [UK] the inhibition of the NFIL3-MYC axis is emerging as a strategy to overcome therapeutic resistance. [Unidentified Country] New therapies, including CAR-T therapies and antibody combinations, are being approved, and FDA data analysis suggests the potential of Teclistamab with Daratumumab.

Made by MielomaAI On November 17, 2026, at 09:45, based on recent news. May contain errors. View news →

Clinical trials

A clinical trial is a study in which a new treatment is compared with the best treatment that already exists. This is how new medicines arrive — and it can give access to them before approval. Taking part is voluntary, at no cost to the patient, and you can withdraw at any time. Ask your haematologist whether there is a trial suitable for your case.

Phase 1First patients: looks for the safe dose.
Phase 2More patients: checks whether the medicine works.
Phase 3Hundreds of patients: compares with the standard treatment. It is the basis for approvals.
Recruiting in Portugal

Multiple myeloma trials with centers in Portugal marked as "recruiting" on ClinicalTrials.gov (updated November 17, 2026). The trial team, in consultation with the patient's hematologist, decides whether a patient can participate.

Phase 3 MagnetisMM-32

Elranatamab (bispecific) alone versus three standard combinations.

For whom: Relapsed patients after anti-CD38 and lenalidomide

In Portugal: Lisbon, Braga

ClinicalTrials.gov · NCT06152575 ↗

Phase 3 MajesTEC-7

Teclistamab or talquetamab (bispecifics) with daratumumab and lenalidomide, versus the standard treatment.

For whom: Newly diagnosed

In Portugal: Braga, Lisbon, Porto

ClinicalTrials.gov · NCT05552222 ↗

Phase 1/2 Surzetoclax

Surzetoclax, a new tablet, alone or with other myeloma medicines. It studies safety and effect.

For whom: Myeloma patients (various stages)

In Portugal: Lisbon, Braga, Porto

ClinicalTrials.gov · NCT06953960 ↗

Phase 3 TRIlogy-7

Ramantamig, a new Janssen medicine, with daratumumab, versus the standard treatments D-VRd or D-Rd.

For whom: Newly diagnosed with no transplant planned

In Portugal: Braga, Lisbon, Porto, Vila Real

ClinicalTrials.gov · NCT07665450 ↗

Phase 3 Linvoseltamab (EMN)

Linvoseltamab (bispecific) versus the standard treatment with daratumumab, lenalidomide and dexamethasone.

For whom: Newly diagnosed who cannot have a transplant

In Portugal: Coimbra, Lisbon

ClinicalTrials.gov · NCT06932562 ↗

Phase 2 TRI Pro

Whether giving tocilizumab before ramantamig prevents cytokine release syndrome (an inflammatory reaction).

For whom: Relapsed patients

In Portugal: Braga, Lisbon, Porto, Vila Nova de Gaia

ClinicalTrials.gov · NCT07589634 ↗

Phase 3 SUCCESSOR-1

Mezigdomide (CELMoD) with bortezomib and dexamethasone, versus pomalidomide, bortezomib and dexamethasone.

For whom: Relapsed patients

In Portugal: Braga, Lisbon, Porto

ClinicalTrials.gov · NCT05519085 ↗

Phase 3 QUINTESSENTIAL-2

BMS-986393, a new CAR-T, versus the standard treatments.

For whom: Relapsed patients who have already had lenalidomide

In Portugal: Porto

ClinicalTrials.gov · NCT06615479 ↗

Sample study EMN36

A European Myeloma Network project that stores biological samples for research. It does not test medicines.

For whom: Myeloma patients

In Portugal: Coimbra, Lisbon, Porto

ClinicalTrials.gov · NCT06237803 ↗
Trials that changed treatment

PERSEUS

Phase 3 Completed · changed practice

What it tested: Adding daratumumab to VRd (bortezomib, lenalidomide and dexamethasone), before and after transplant.

For whom: Newly diagnosed patients who can have a transplant.

Results

PERSEUS (with transplant): progression-free at 4 years

D-VRd (with daratumumab)84,3%
VRd67,7%
Source: ASCO Post ↗
Known side effects

PERSEUS: severe effects (grade 3 or 4), with and without daratumumab

Neutropenia — D-VRd62,1%
Neutropenia — VRd51%
Low platelets — D-VRd29,1%
Low platelets — VRd17,3%
Pneumonia — D-VRd10,5%
Pneumonia — VRd6,1%
Source: CancerNetwork ↗

any grade severe (grade 3 or higher)

Source: ASCO Post ↗

CEPHEUS

Phase 3 Completed (final analysis in 2026)

What it tested: Adding daratumumab to VRd in people who do not have a transplant or postpone it.

For whom: Newly diagnosed patients with no transplant planned.

Results

Patients without transplant treated with D-VRd

Complete response or better80,6%
No detectable disease (MRD negative)60,4%
Source: HMP Global ↗
Known side effects

D-VRd in CEPHEUS (with bortezomib and lenalidomide)

Infections91,9% (grave 40,1%)
Diarrhoea56,9%
Peripheral neuropathy (tingling, numbness)55,8%
Neutropenia55,8% (grave 44,2%)
Low platelets46,7% (grave 28,4%)

Neuropathy is mainly linked to bortezomib; giving bortezomib under the skin and once a week helps reduce it.

Source: CancerNetwork ↗

any grade severe (grade 3 or higher)

D-VRd reduced the risk of progression or death by 43% compared with VRd.

Source: Pharmacy Times ↗

IMROZ

Phase 3 Completed · changed practice

What it tested: Adding isatuximab to VRd.

For whom: Newly diagnosed patients who cannot have a transplant.

Results

IMROZ (without transplant): progression-free at 5 years

Isa-VRd (with isatuximab)63,2%
VRd45,2%
Source: ESMO ↗
Source: ESMO ↗

DETERMINATION

Phase 3 Completed

What it tested: Having the transplant straight away, or keeping it for later, after VRd.

For whom: Newly diagnosed patients who can have a transplant.

Results

DETERMINATION: median progression-free time

VRd + transplant67,5 meses
VRd without immediate transplant46,2 meses
Source: ASCO Post ↗

DETERMINATION: alive at 5 years (survival was similar)

With transplant80,7%
Without immediate transplant79,2%
Source: ASCO Post ↗
Source: ASCO Post ↗

CARTITUDE-4

Phase 3 Completed · in follow-up

What it tested: A single infusion of cilta-cel (CAR-T) versus the standard treatments.

For whom: Relapsed patients, from the 2nd line, resistant to lenalidomide.

Results

CARTITUDE-4 (cilta-cel, from the 2nd line): median progression-free time

Cilta-cel (Carvykti)ainda não atingida
Standard treatment11,8 meses
Source: CancerNetwork, janeiro de 2026 ↗

CARTITUDE-4 (cilta-cel, from the 2nd line): patients after two and a half years

Progression-free — cilta-cel59,4%
Progression-free — standard treatment25,7%
Alive — cilta-cel76,4%
Alive — standard treatment63,8%
Source: CancerNetwork, janeiro de 2026 ↗
Known side effects

Cilta-cel in CARTITUDE-4 (176 patients)

Cytokine release syndrome (fever, low blood pressure)76% (grave 1%)
Nervous system effects (all)21% (grave 3%)
ICANS (confusion, difficulty speaking)5% (grave 0%)
Other neurological effects17% (grave 2%)
Source: Legend Biotech, ASH ↗

CARTITUDE-4: severe effects, cilta-cel versus standard treatment

Severe infections — cilta-cel27%
Severe infections — standard25%
Severe drop in blood cells — cilta-cel94%
Severe drop in blood cells — standard86%
Source: Johnson & Johnson ↗

any grade severe (grade 3 or higher)

Source: CancerNetwork ↗

CARTITUDE-1

Phase 1b/2 Completed · long follow-up

What it tested: Cilta-cel (CAR-T) in patients who had already had many treatments.

For whom: Patients with, on average, 6 previous treatments.

Results

CARTITUDE-1 (cilta-cel, patients with many previous treatments): medians

Median progression-free time34,9 meses
Median survival60,7 meses
Source: CancerNetwork, junho de 2025 ↗

CARTITUDE-1: patients without progression and without any other treatment 5 years or more after a single infusion

Cilta-cel (Carvykti)33%
Source: Targeted Oncology, junho de 2025 ↗
Source: CancerNetwork ↗

KarMMa-3

Phase 3 Completed

What it tested: Ide-cel (Abecma, CAR-T) versus standard treatments.

For whom: Relapsed patients after 2 to 4 treatments.

Results

Ide-cel (Abecma) versus standard treatments: average time without worsening

Ide-cel (Abecma)13,8 meses
Standard treatment4,4 meses
Source: EMA — Abecma ↗

Patients who responded

Responded — ide-cel71%
Responded — standard42%
Complete response — ide-cel44%
Complete response — standard5%
Source: Blood (análise atualizada) ↗
Source: Blood / PubMed ↗

iMMagine-1

Phase 2 FDA decision on 23/12/2026

What it tested: Anito-cel, a new CAR-T, in a single infusion.

For whom: Relapsed patients after 3 or more treatments.

Results

Results in the 117 patients

Responded97%
Complete response or better68%
Source: Arcellx (Business Wire) ↗
Source: Pharmacy Times ↗

CAR-T in vivo (KLN-1010 e ESO-T01)

Phase 1 Under study · not yet approved

What it tested: A single infusion that turns T cells inside the body into CAR-T against BCMA: no cell collection, no factory and no conditioning chemotherapy.

For whom: Relapsed patients after several treatments (Australia, USA and China). There are no trials in Portugal yet.

Results

First results (few patients, short follow-up)

KLN-1010: no detectable disease (MRD negative) at month 1 — 4 of 4 patients100%
ESO-T01: cancer eliminated — 3 of 5 patients60%
Source: Kelonia (ASH 2025) / Fierce Biotech (Nature Medicine 2026) ↗

In the ESO-T01 trial one patient with a lesion outside the bone marrow (spinal cord compression) died. The authors call for more care in selecting patients with this type of lesion.

Source: Fierce Biotech ↗

MajesTEC-3

Phase 3 Completed · approved in Europe (2026)

What it tested: Teclistamab (bispecific) with daratumumab.

For whom: Relapsed patients, from the 2nd line.

Results

MajesTEC-3 (teclistamab + daratumumab): alive at 3 years

Teclistamab + daratumumab83,3%
Standard treatment65%
Source: FDA ↗
Source: FDA ↗

MagnetisMM-32

Phase 3 Main results in October 2026

What it tested: Elranatamab alone versus three standard combinations.

For whom: Relapsed patients after anti-CD38 and lenalidomide.

Results

Elranatamab: initial results

Progression-free at 18 months68%
Severe infections (grade 3 or higher)27,5%
Source: IMF ↗

Median progression-free time has not yet been reached. There is a trial recruiting in Lisbon and Braga.

Source: Targeted Oncology ↗

DREAMM-7

Phase 3 Completed · approved

What it tested: Belantamab with bortezomib and dexamethasone (BVd) versus daratumumab with bortezomib and dexamethasone.

For whom: Relapsed patients, from the 2nd line.

Results

DREAMM-7 (BVd versus DVd)

Progression-free at 1 year — BVd71%
Progression-free at 1 year — standard51%
Alive at 3 years — BVd74%
Alive at 3 years — standard60%
Source: Ashtons / NICE ↗
Known side effects

Belantamab in DREAMM-7: eye effects

Eye effects — BVd (with belantamab)79%
Eye effects — DVd29%
Blurred vision — BVd66%
Severe corneal and vision changes — BVd77%

In most cases they improve when the dose is delayed or reduced. Regular eye appointments are needed.

Source: NEJM (DREAMM-7) / CancerNetwork ↗

any grade severe (grade 3 or higher)

Source: NICE ↗

DREAMM-8

Phase 3 Completed · in follow-up

What it tested: Belantamab with pomalidomide and dexamethasone (BPd) versus pomalidomide, bortezomib and dexamethasone (PVd).

For whom: Relapsed patients who have already had lenalidomide.

Results

Median progression-free time

BPd (with belantamab)32,6 meses
PVd12,5 meses
Source: CancerNetwork, dezembro de 2025 ↗
Source: Targeted Oncology ↗

SUCCESSOR-2

Phase 3 Results in May 2026

What it tested: Mezigdomide (CELMoD) with carfilzomib and dexamethasone.

For whom: Relapsed patients.

Results

SUCCESSOR-2 (mezigdomide + Kd versus Kd): median progression-free time

MeziKd18 meses
Kd8,3 meses
Source: Indian Pharma Post, maio de 2026 ↗

The sister trial, SUCCESSOR-1, is recruiting in Porto, Lisbon and Braga.

Source: IMF ↗

AQUILA

Phase 3 Completed · approved

What it tested: Daratumumab versus monitoring only.

For whom: People with high-risk smouldering myeloma.

Results

AQUILA (high-risk smouldering myeloma), at 5 years

Progression-free — daratumumab63,1%
Progression-free — monitoring only40,8%
Alive — daratumumab93%
Alive — monitoring only87%
Source: AJMC / NEJM ↗
Source: AJMC / NEJM ↗

How to read the numbers: “median progression-free time” is the time after which half of the patients still did not have their disease getting worse; “not yet reached” means that, when the study was published, more than half were still progression-free. These are results from selected patients and do not say what will happen to each person.

Side effects: what the trials show

Percentage of patients in each trial who had each effect. The light bar is any grade; the dark part is severe cases (grade 3 or higher). The numbers come from selected patients and do not say what will happen to each person; many effects are prevented or treated by the team.

CAR-T

Cilta-cel in CARTITUDE-4 (176 patients)

Cytokine release syndrome (fever, low blood pressure)76% (grave 1%)
Nervous system effects (all)21% (grave 3%)
ICANS (confusion, difficulty speaking)5% (grave 0%)
Other neurological effects17% (grave 2%)
Source: Legend Biotech, ASH ↗

CARTITUDE-4: severe effects, cilta-cel versus standard treatment

Severe infections — cilta-cel27%
Severe infections — standard25%
Severe drop in blood cells — cilta-cel94%
Severe drop in blood cells — standard86%
Source: Johnson & Johnson ↗

any grade severe (grade 3 or higher)

Bispecific antibodies

Teclistamab in MajesTEC-1 (165 patients)

Infections76,4% (grave 44,8%)
Cytokine release syndrome72,1% (grave 0,6%)
Neutropenia (low white blood cells)70,9% (grave 64,2%)
Anaemia52,1% (grave 37%)
ICANS (neurological effects)3% (grave 0%)
Source: New England Journal of Medicine (PMC) ↗

Talquetamab in MonumenTAL-1: effects specific to this medicine

Change in taste77%
Skin (dryness, peeling, itching)73%
Nails63%
Source: Healio, ASH 2023 ↗

any grade severe (grade 3 or higher)

Belantamab (ADC)

Belantamab in DREAMM-7: eye effects

Eye effects — BVd (with belantamab)79%
Eye effects — DVd29%
Blurred vision — BVd66%
Severe corneal and vision changes — BVd77%

In most cases they improve when the dose is delayed or reduced. Regular eye appointments are needed.

Source: NEJM (DREAMM-7) / CancerNetwork ↗

any grade severe (grade 3 or higher)

Anti-CD38 antibodies

Daratumumab: reactions during administration (COLUMBA)

In the belly, subcutaneous (3 to 5 minutes)13% (grave 2%)
Into a vein, intravenous (several hours)34% (grave 5%)
Source: OncLive / Haematologica ↗

PERSEUS: severe effects (grade 3 or 4), with and without daratumumab

Neutropenia — D-VRd62,1%
Neutropenia — VRd51%
Low platelets — D-VRd29,1%
Low platelets — VRd17,3%
Pneumonia — D-VRd10,5%
Pneumonia — VRd6,1%
Source: CancerNetwork ↗

any grade severe (grade 3 or higher)

Combinations with bortezomib and lenalidomide

D-VRd in CEPHEUS (with bortezomib and lenalidomide)

Infections91,9% (grave 40,1%)
Diarrhoea56,9%
Peripheral neuropathy (tingling, numbness)55,8%
Neutropenia55,8% (grave 44,2%)
Low platelets46,7% (grave 28,4%)

Neuropathy is mainly linked to bortezomib; giving bortezomib under the skin and once a week helps reduce it.

Source: CancerNetwork ↗

any grade severe (grade 3 or higher)

Trial news by year

2026

  1. 27 Oct 2026
    Trial Elranatamab alone beats three standard regimens (MagnetisMM-32)

    Phase 3 trial with 523 patients relapsing after anti-CD38 and lenalidomide: it met its main goal (progression-free time). More severe infections in the elranatamab arm.

    Source: IMF ↗
  2. 11 Jun 2026
    Trial In vivo CAR-T KLN-1010: deep responses without conditioning chemotherapy

    Updated data from the phase 1 trial (ASCO and EHA 2026 congresses): evaluable patients had no detectable disease, with the CAR-T created inside the body from a single infusion.

    Source: Targeted Oncology ↗
  3. 2 Jun 2026
    Trial CEPHEUS: final analysis confirms daratumumab in the first line without transplant

    With more than 6 years of follow-up, adding daratumumab to VRd gave deeper and longer-lasting responses in patients who do not have a transplant.

    Source: Pharmacy Times ↗
  4. 30 May 2026
    Trial Mezigdomide halves the risk of progression (SUCCESSOR-2)

    Presented at the ASCO congress: median progression-free time of 18 months with MeziKd versus 8.3 months with Kd.

    Source: Targeted Oncology ↗
  5. 25 Mar 2026
    Trial In vivo CAR-T ESO-T01 published in Nature Medicine

    First complete study of a CAR-T made inside the body in myeloma: the cancer was eliminated in 3 of 5 patients, but one patient died from a complication linked to a lesion outside the bone marrow.

    Source: Fierce Biotech ↗
  6. 20 Jan 2026
    Trial iMMagine-1: anito-cel with 97% responses

    Phase 2 trial with 117 heavily treated patients: 97% responded and 68% had a complete response or better, with a single infusion.

    Source: Multiple Myeloma Hub ↗

2025

  1. 10 Dec 2025
    Trial DREAMM-8: belantamab triples progression-free time

    With longer follow-up, median progression-free time was 32.6 months with BPd versus 12.5 months with PVd, in patients who had already had lenalidomide.

    Source: CancerNetwork ↗
  2. 9 Dec 2025
    Trial First patients treated with in vivo CAR-T KLN-1010

    At the ASH 2025 congress: the first 4 patients had no detectable disease after 1 month, with no cell collection, no factory and no conditioning chemotherapy.

    Source: OncLive ↗
  3. 6 Dec 2025
    Trial CARTITUDE-4: 80% progression-free at two and a half years in standard risk

    In patients with standard-risk cytogenetics treated with cilta-cel, 80.5% were progression-free and 87.3% alive at 30 months (ASH 2025 congress).

    Source: OncLive ↗
Expected results
  1. 12 Dec 2026
    ASH 2026 Congress (New Orleans, 12–15 Dec.)

    The biggest haematology congress of the year, with new data on CAR-T, bispecifics and first line.

    Source: ASH ↗
  2. 23 Dec 2026
    US decides on anito-cel, a new CAR-T

    FDA target date for the accelerated approval of anitocabtagene autoleucel (iMMagine-1 trial).

    Source: Targeted Oncology ↗
  3. 2027
    Elranatamab in earlier lines goes for review

    With the MagnetisMM-5 and MagnetisMM-32 results, Pfizer announced it will submit the data to the agencies.

    Source: Fierce Pharma ↗
  4. 2027
    Mezigdomide: data submitted to health authorities

    After SUCCESSOR-2, an approval application is expected. There is no decision date yet.

    Source: IMF ↗
  5. 2027
    CAR-T as first-line treatment: results awaited

    The CARTITUDE-5 (no transplant) and CARTITUDE-6 (CAR-T instead of transplant) trials have not yet published results (October 2026). No official date.

    Source: J&J Medical Connect ↗
Where to look for trials

Questions about your rights in a trial? Ask MielomaAI in Where to find help (“Can I take part in a clinical trial?”). This site does not replace your doctor.

Latest news on treatments

All news → · Summaries created by MielomaAI; expand the article to read the original.